SCM
DFTX

Soleus Capital Management’s Definium Therapeutics DFTX Stock Holding History

Soleus Capital Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-750,237
Closed -$7.05M – 105
2024
Q1 		$7.05M Buy
+750,237
New +$4.28M 0.52% 56

Other funds holding DFTX

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Soleus Capital Management's DFTX Position: Q2 2024 in Review

Soleus Capital Management sold out of Definium Therapeutics (DFTX) in Q2 2024, closing a stake of 750,237 shares — an estimated $7.05M sold.

Soleus Capital Management first reported a position in DFTX in Q1 2024 and held it in 1 quarter. The position peaked at $7.05M in Q1 2024. 151 funds tracked by Wall St. Rank hold DFTX as of Q2 2024.

  • Soleus Capital Management reported no remaining Definium Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Soleus Capital Management sold 750,237 Definium Therapeutics shares in Q2 2024, an estimated $7.05M.
  • Soleus Capital Management first reported a position in Definium Therapeutics in Q1 2024 and held it in 1 quarter.
  • Soleus Capital Management's Definium Therapeutics position peaked at $7.05M in Q1 2024.
  • 151 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2024.

Based on Soleus Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.